PositiveID Subsidiary ExcitePCR Announces Board of Advisors Dr.
R. Paul Schaudies, Charles Pick and Dr. Anilrudh Venugopal bring
broad industry expertise and skilled leadership to ExcitePCR to
help drive commercialization of FireflyDX
Delray Beach, FL -- September 26, 2017 -- InvestorsHub NewsWire
-- PositiveID Corporation (OTCQB:
PSID), a life sciences company focused on detection and
diagnostics, announced today its ExcitePCR Corporation subsidiary
has formed a board of advisors, which includes Dr. R. Paul
Schaudies, Charles Pick and Dr. Anilrudh Venugopal. The advisors
industry expertise ranges from biodefense and molecular diagnostics
to agricultural genomics and infectious diseases.
Dr. R. Paul Schaudies is the CEO and co-founder of GenArraytion,
a molecular diagnostics company, and an internationally recognized
expert in biodefense, biotechnology and nanotechnology. Dr.
Schaudies was the science advisor to the EPA On-Scene Coordinator,
and Incident Commander of the 2001 anthrax incident in Washington,
DC. As a US Army Officer, he supported the United Nations as an
UNSCOM inspector in Iraq. He was an AVP and Division Manager for
Biological and Chemical Defense at Science Applications
International Corporation for nine years, and spent 13 years as an
active duty US Army officer and retired as a Lieutenant Colonel in
the USAR. Dr. Schaudies was the Program Manager for Biological and
Chemical Defense Research in the Central MASINT Office at the
Defense Intelligence Agency, and a Senior Researcher at the Walter
Reed Army Institute of Research with over 25 peer reviewed
scientific publications.
Charles Pick is the President of seqID inc., which specializes
in agricultural genomic technologies. Mr. Pick received his BSc in
Immunology at University of Toronto and his MBA at Queens
University (Smith School of Business). He has more than 25 years of
experience in the agriculture and biotechnology industries. He
began his career in the seed industry becoming VP of Canadian turf
operations at the Pickseed Companies Group before becoming head of
business development for BASFs agricultural genomics division (DNA
LandMarks) for 11 years. In 2014, Mr. Pick launched seqID with the
aim of bringing the latest genomic technologies and services to the
agricultural sector.
Dr. Anilrudh Venugopal is a board certified Infectious Diseases
and Internal Medicine physician with more than 15 years of clinical
experience. He previously held academic faculty appointments at the
Wayne State School of Medicine and the Loyola University Chicago
Stritch School of Medicine. He has a strong research background
with numerous publications and presentations on MRSA and
Clostridium difficile infections. He also consults with
pharmaceutical and medical device companies to assess the potential
impact of their products and helps develop strategy to target and
bring products to market.
We brought these highly regarded industry experts on board to
help accelerate value creation at ExcitePCR, stated Lyle L. Probst,
CEO, President and Founder of ExcitePCR. We believe that utilizing
their relevant experience, insights and relationships enhances our
ability to execute on our plans to complete the development of
FireflyDX and achieve exponential growth for our company and our
shareholders.
In May 2017, PositiveID formed ExcitePCR to own and further
develop the assets of FireflyDX, which is designed to be a
handheld, fully automated, lab quality, real-time device able to
process samples and detect pathogens at the point of need or point
of care, faster and less expensively than existing devices, without
the need to return the sample to a lab for a confirmatory result.
FireflyDX's applications include lab-quality, sample processing and
detection of pathogenic organisms; agricultural and food screening
in both domestic sectors and developing countries; and detection of
biological agents associated with weapons of mass destruction.
About PositiveID Corporation
PositiveID Corporation is a holding company focused on life
sciences, diagnostics, mobile laboratories, and medical devices.
PositiveIDs ExcitePCR subsidiary is developing the FireflyDX
family of pathogen detection systems, portable devices offering
rapid sample-to-result detection in less than 30 minutes using
real-time polymerase chain reaction chemistry. PositiveIDs E-N-G Mobile
Systems subsidiary is a leader in the mobile technology vehicle
market, with a focus on the laboratory market and homeland
security. PositiveIDs Thermomedics subsidiary markets the
FDA-cleared Caregiver non-contact thermometer for clinical use. For
more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on
Twitter, Facebook or LinkedIn.
On August 24, 2017, PositiveID Corporation and its wholly-owned
subsidiary PositiveID Diagnostics, Inc. (collectively, the Seller),
entered into an Asset Purchase Agreement (APA) with ExcitePCR
Corporation. Pursuant to the APA, at closing, the Seller will sell
and deliver to ExcitePCR all assets used in connection with the
operation of the FireflyDX technology. For more information on the
APA, please read PositiveIDs Form 8-K filed on August 28, 2017,
which can be found here.
Statements about PositiveID's (the Company) future expectations,
including the likelihood that these highly regarded industry
experts will help accelerate value creation at ExcitePCR; the
likelihood that utilizing their relevant experience, insights and
relationships enhances ExcitePCRs ability to execute on its plans
to complete the development of FireflyDX and achieve exponential
growth for the company and its shareholders; the likelihood that
FireflyDX is designed to be a handheld, fully automated, lab
quality, real-time device able to process samples and detect
pathogens at the point of need or point of care, faster and less
expensively than existing devices, without the need to return the
sample to a lab for a confirmatory result; the likelihood that
FireflyDX's applications include lab-quality, sample processing and
detection of pathogenic organisms, agricultural and food screening
in both domestic sectors and developing countries, and detection of
biological agents associated with weapons of mass destruction; the
likelihood that pursuant to the APA, at closing, the Seller will
sell and deliver to ExcitePCR all assets used in connection with
the operation of the FireflyDX technology; constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties and are subject to change at any time, and
PositiveID's actual results could differ materially from expected
results. These risks and uncertainties include, without limitation,
PositiveIDs and ExcitePCRs ability to raise capital; PositiveIDs
and ExcitePCRs ability complete the testing and development of
Firefly Dx; as well as other risks. Additional information about
these and other factors that could affect PositiveID's business is
set forth in its various filings with the Securities and Exchange
Commission, including those set forth in its 10-K filed on March
31, 2017, and 10-Qs filed on August 14, 2017, May 15, 2017, and
November 18, 2016, under the caption "Risk Factors." PositiveID
undertakes no obligation to update or release any revisions to
these forward-looking statements to reflect events or circumstances
after the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Contacts:
PositiveID Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com